Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition. by Aggarwal, Ajay et al.
Aggarwal, A; Lewis, D; Charman, SC; Mason, M; Clarke, N; Sul-
livan, R; van der Meulen, J (2017) Determinants of Patient Mo-
bility for Prostate Cancer Surgery: A Population-based Study of
Choice and Competition. European urology. ISSN 0302-2838 DOI:
https://doi.org/10.1016/j.eururo.2017.07.013
Downloaded from: http://researchonline.lshtm.ac.uk/4209919/
DOI: 10.1016/j.eururo.2017.07.013
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
 
 
Determinants of patient mobility for prostate cancer surgery: a population-1 
based study of choice and competition  2 
 3 
Ajay Aggarwal MD,a* Daniel Lewis PhD,b Susan C. Charman PhD,c Malcolm Mason MD,d 4 
Noel Clarke MD,e Richard Sullivan MD,f Jan van der Meulen PhDa,c 5 
 6 
a) Department of Health Services Research & Policy, London School of Hygiene and 7 
Tropical Medicine, London, UK 8 
b) Department of Social and Environment Health Research, London School of 9 
Hygiene and Tropical Medicine, London, UK 10 
c) Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK 11 
d) School of Medicine, Cardiff University, Cardiff, UK 12 
e) The Christie and Salford Royal NHS Foundation Trust, Manchester, UK 13 
f) Institute of Cancer Policy, King’s College London, London, UK 14 
 15 
 16 
*Address for correspondence 17 
Dr Ajay Aggarwal 18 
Department of Health Services Research & Policy 19 
London School of Hygiene and Tropical Medicine 20 
15-17 Tavistock Place 21 
London 22 
WC1H 9SH 23 
Email: ajay.aggarwal@lshtm.ac.uk Tel: 02079272135 24 
 25 
KEY WORDS:  26 
Patient mobility; patient choice; provider competition; equity; cancer; robotic surgery; 27 
reputation 28 
 29 
WORD COUNT: 1754 30 
 31 
 32 
2 
 
 
 
ABSTRACT 33 
Many countries have introduced policies that enable patients to select a health care 34 
provider of their choice with the aim of improving the quality of care. However, there is 35 
little information about the drivers or the impact of patient mobility. Using administrative 36 
hospital data (n=19,256) we analysed the mobility of prostate cancer patients who had 37 
radical surgery in England between 2010 and 2014. Our analysis, using geographic 38 
information systems and multivariable choice modelling, found that 33·5% (n= 6,465) of 39 
men bypassed their nearest prostate cancer surgical centre. Travel time had a strong impact 40 
on where patients moved to but was less of a factor for men who were younger, fitter, and 41 
more affluent (p always <0·001). Men were more likely to move to hospitals that provided 42 
robotic prostate cancer surgery (odds ratio 1·42, p<0·001) and to hospitals that employed 43 
surgeons with a strong media reputation (odds ratio 2·18, p<0·001). Patient mobility 44 
occurred in the absence of validated measures of the quality of care, instead influenced by 45 
the adoption of robotic surgery and the reputation of individual clinicians. National policy 46 
based on patient choice and provider competition may have had a negative impact on 47 
equality of access, service capacity, and health system efficiency. 48 
Patient summary 49 
In this study we assessed the reasons why men would choose to have prostate cancer 50 
surgery at a centre other than their nearest. We found that in England men were attracted 51 
to centres that carried out robotic surgery and employed surgeons with a national 52 
reputation. 53 
 54 
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Many high-income countries have introduced policies that aim to improve the quality of 55 
care by stimulating competition between hospital providers and allowing patients to choose 56 
the hospital where they have treatment.1 In publicly funded health care markets such as the 57 
UK, funding follows the patient, creating quite powerful incentives for hospitals to attract 58 
new patients by demonstrating superior quality.2 59 
 60 
To date, our understanding of the extent and determinants of patient mobility across health 61 
services remains limited, due to a paucity of available research and heterogeneity in the 62 
design of empirical studies.3 The aim of the present study is to undertake the first-ever 63 
national analysis assessing the impact of choice and competition policies within cancer care. 64 
Our aim was to investigate whether prostate cancer patients, who had a radical 65 
prostatectomy (RP) in the English NHS, travelled beyond (“bypassed”) their nearest hospital, 66 
and the hospital and patient characteristics associated with that mobility.  67 
 68 
We obtained individual patient-level data on all men (n=19, 256) who were diagnosed with 69 
prostate cancer and underwent RP in the English NHS between 1st January 2010 and 31st 70 
December 2014 from the National Cancer Registration and Analysis Service (NCRAS) and 71 
linked at patient level to Hospital Episode Statistics (HES).  Patient characteristics of the 72 
study cohort are presented in Supplementary Table 1. 73 
 74 
The population weighted centroids of the patients’ Lower Super Output Areas (geographic 75 
areas defined by the Office for National Statistics that typically includes 1,500 residents or 76 
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650 households) and the full postcodes for the hospitals where the surgery was undertaken 77 
were inputted into a geographical information system (ESRI ArcGIS 10.3) to calculate travel 78 
times according to the fastest route by car (using Ordnance Survey MasterMap Integrated 79 
Transport Network). For each patient, the travel time to all prostate cancer surgical centres 80 
(n=65) was calculated. The proportion of patients not receiving care at their nearest centre 81 
were considered to be “bypassers”. 82 
 83 
We determined three hospital-level characteristics. These were informed by a systematic 84 
review of the literature and qualitative interviews with both men previously treated for 85 
prostate cancer and uro-oncology specialists currently practicing in the UK. 86 
 87 
We labelled the 12 hospitals that carried out robotic prostatectomies at the start of the 88 
study period as “established robotic centres”. We identified the 31 “university teaching 89 
hospitals”, based on their membership of the Association of UK University Hospitals. We 90 
also defined the 12 hospitals with a “strong media reputation”, based on whether or not 91 
they employed urologists that were listed in 2010 as the “best” prostate cancer surgeons in 92 
the UK by the “Daily Mail”,4 which is the only nationally published source recognising expert 93 
prostate cancer surgeons. Further details on selection of hospital characteristics is available 94 
in the supplemental content. 95 
 96 
Conditional logit regression was used to model the odds that a patient moved to a particular 97 
hospital as a function of travel time and hospital and patient characteristics.5 For each 98 
patient, we created a data set that included for each patient a row for each hospital 99 
providing prostate cancer surgery at the time of treatment (number of hospitals varied 100 
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between 57 and 65 as eight hospitals closed during the study period). The dependent 101 
variable of the conditional logit model was a dummy variable with a value of 1 for the 102 
hospital where a patient had his treatment and a value of 0 otherwise. Patient 103 
characteristics were included as interaction terms with travel time in the model and 104 
included age, number of comorbidities, socioeconomic status (based on national quintiles of 105 
the Index of Multiple Deprivation)6,and urban or rural residence.7 Further detail on patient 106 
characteristics and the statistical methods is available in the supplemental content. 107 
 108 
Our analysis demonstrated that 6,465 men (33·5%) “bypassed” the nearest centre that 109 
carried out prostate cancer surgery. 2386 men (12·4%) bypassed at least three hospitals for 110 
their treatment and 1,258 men (6·5%) at least five hospitals (Supplementary Table 2). There 111 
were clear differences in bypass rates between the nine English regions. In London, 50·9% of 112 
men had their prostate cancer surgery at the nearest centre whilst corresponding 113 
percentages were 86·5% in the North East and 80·6% in Yorkshire and Humberside 114 
(Supplementary Table 3).  115 
 116 
Travel time had a strong impact on the odds that a patient chose a particular hospital to 117 
receive surgery. The odds of a patient choosing a hospital that was up to 10 minutes further 118 
away than the patient’s nearest hospital that carried out prostate cancer surgery was found 119 
to be on average 78% smaller (OR of 0.22). The odds decreased markedly as the additional 120 
travel time increased (Table 1). 121 
 122 
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The addition of patient characteristics as interaction terms into our model demonstrated 123 
that the impact of travel time was smaller for men who were younger, for those who were 124 
fitter (no recorded comorbidities), and for those who lived in more affluent or rural areas 125 
(odds ratios larger than “1” (Table 1)). For example, again compared to having the surgery at 126 
the nearest hospital, for men in rural areas, the likelihood of moving to a hospital that was 127 
up to 10 minutes further away was estimated to be 2·5 times smaller (= 1 / (0·22 x 1·79)) 128 
whereas the corresponding figure for men from urban areas is 4.8 (= 1 / 0·22). 129 
 130 
Patients were 1·42 times more likely to move to one of the 12 hospitals that were 131 
established robotic centres compared to those that were not and 2·18 times more likely to 132 
move to the 12 hospitals that employed surgeons who had a strong media reputation (Table 133 
1). University teaching hospital status had a small but statistically significant impact (OR 134 
1·09, p<0·001) on attracting patients. 135 
 136 
These findings have a number of policy implications that are relevant across a range of 137 
elective secondary care services in countries that have introduced patient choice of provider 138 
policies.3 A substantial number of patients, well above the 5% to 10% thought to be 139 
necessary to incentivise improvements in quality,8 were prepared to move to hospitals 140 
further away for radical prostatectomy. This occurred in the absence of evidence that these 141 
hospitals achieved better outcomes. Instead, they responded to the availability of more 142 
advanced surgical technology and the perceived reputation of the hospitals’ surgeons.  143 
 144 
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The provision of robotic surgery has been noted to attract patients to providers in health 145 
care markets across Europe and North America,9 resulting in a rapid growth in the number 146 
of providers offering this technology. Our own data supports this: men were more likely to 147 
choose one of the 12 established robotic centres in the NHS. It is likely that this competitive 148 
advantage has contributed to the large-scale investment in equipment for robotic surgery 149 
across the NHS.10 There has been a more than threefold increase in the number of centres 150 
offering this modality between 2010 and 2016 (from 12 to 42 centres). 151 
 152 
Hospital and clinician reputation have also been identified in other studies as important 153 
factors influencing decision making for cancer surgery.11 This suggests that patients, with or 154 
without guidance from their primary care physician, social and medical networks or clinician 155 
who diagnosed the cancer, respond to indicators that in their view reflect differences in 156 
treatment quality.12 157 
 158 
The list of prostate cancer surgeons with a national reputation was compiled by the Daily 159 
Mail following a survey of urologists working in the UK. Much of the intelligence is therefore 160 
likely to be representative of the discussions that are ongoing within particular regions both 161 
amongst clinicians as well as patient and carer support groups. It can therefore be 162 
considered as a proxy for the wider reputation of hospitals. 163 
  164 
The patterns of mobility observed in England has resulted in large and unexpected shifts in 165 
market share for hospitals carrying out prostate cancer surgery. For some hospitals, nearly 166 
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80% of patients for whom that hospital was the nearest provider chose to have their 167 
treatment elsewhere. Conversely, other hospitals were performing up to 200% more 168 
operations than expected because patients from elsewhere travelled to these hospitals for 169 
their surgery. Such extremes of mobility are likely to have a negative impact on health 170 
system efficiency (due to lengthening waiting lists for some and unused capacity for others) 171 
with some surgical units facing the threat of closure  given that funding is contingent on the 172 
number of procedures performed.2,10 Equally, surgical unit closures and the greater 173 
regionalization that results may serve to improve efficiency.  174 
 175 
Our modelling of patient mobility had a number of limitations.  First, we used administrative 176 
dataset and it is likely that we have missed less severe comorbid conditions. Second, the 177 
study used centroids of small geographical areas to represent the location of the patients’ 178 
residence. This will have added “noise” to the determination of travel times. 179 
 180 
In conclusion, men are willing to travel for prostate cancer surgery, especially those that are 181 
relatively young, fit and affluent. The study highlights that without appropriate quality 182 
information to guide patients’ choices, patients are influenced by the reputation of hospitals 183 
and their surgeons and the availability of innovative technologies. National policy based on 184 
patient choice and provider competition may have a negative impact on service capacity, 185 
equality of access, and health system efficiency. 186 
  187 
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Table 1 – Impact of travel time and hospital and patient characteristics on patient mobility in 19,256 232 
men undergoing radical prostatectomy between 2010-2014 in the English National Health Service.1 233 
 234 
  
Adjusted 
odds ratio 
95% CI 
p 
value2 
Impact of additional travel time (mins)3 
   1  <0.001 
  <10  0.22 0.18-0.27  
  11-30  0.03 0.03-0.04  
  31-60  0.004 0.003-0.006  
  >60  0.0005 0.0003-0.0006  
     
Difference in impact of additional travel time for 
selected patient characteristics4 
 Younger patients (< 65 years) 
 
  
<0.001 
  <10  1.11 1.01-1.23 
 
  11-30  1.14 1.02-1.28 
  31-60  1.40 1.20-1.64 
  >60  1.37 1.18-1.59 
 Patients without comorbidities    <0.001 
  <10  1.16 0.97-0.98 
 
  11-30  1.12 0.90-1.39 
  31-60  1.78 1.23-2.58 
  >60  1.32 0.97-1.81 
 Patients from more affluent areas (IMD 1 or 2)    <0.001 
  <10  1.08 0.98-1.23 
 
  11-30  1.36 1.21-1.52 
  31-60  1.35 1.15-1.59 
  >60  1.12 0.97-1.29 
 Patients from rural areas    <0.001 
  <10  1.79 1.57-2.04 
 
  11-30  2.19 1.93-2.48 
  31-60  2.61 2.23-3.05 
  >60  2.14 1.84-2.47 
  
   
Impact of hospital characteristics     
 University hospital  1.09 1.05-1.15 <0.001 
 Established robotic centre   1.42 1.33-1.52 <0.001 
 Strong media reputation   2.18 2.05-2.31 <0.001 
     
     
McFadden’s pseudo R2   0.70  
 235 
Notes: 236 
1. Odds ratio represent differences in the odds that a patient moves to a particular hospital as a function 237 
of travel time and hospital and patient characteristics. 238 
2. P value based on likelihood ratio test 239 
3. Note that the adjusted odds ratios for additional travel time relates to older men (≥ 65 years), with 240 
comorbidity (Charlson ≥ 1), from less affluent (IMD 3-5), and living in an urban area.  241 
4. Impact of patient characteristics on the odds ratio representing the impact of additional travel time 242 
(see results section for interpretation). 243 
